Keting Chu is Ventur Partner of Lyfe Capital that is focused on healthcare VC investments in the US and China. Keting is a scientist, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development and venture investment.
Prior to joining Lyfe Capital, Dr. Chu was venture partner at Apple Tree Partners. Before joining Apple Tree Partners, Keting spent five years as VP, Research TAP at The Leukemia and Lymphoma Society (LLS), and is responsible for venture philanthropy. Prior to LLS, Keting co-founded, as head of RnD or CEO, four biotech companies including Five Prime Therapeutics, Bio3, DigitAB and Mission therapeutics. Before that, Keting was the Head of Immunotherapy and Antibody Therapeutics Division at Chiron Corporation and she was responsible for the R&D pipeline of biologic.
Keting received her MD in Sun Yat-sen Medical University specialized in infectious diseases in China, Ph.D. in Microbiology and Immunology at University of California at San Francisco (UCSF).